Because MCL-1 overexpression may be involved in resistance to Ven plus HMAs, inhibiting MCL-1 could potentially increase the efficacy of HMAs against AML, especially in cells expressing high MCL-1 levels (18). This evidence concerns the gene MCL1 and acute myeloid leukemia.